From OT Europe

Zimmer Biomet announces international release of procedure for bone marrow lesions

Zimmer Biomet Holdings Inc. announced the international release of the subchondroplasty procedure, a minimally invasive outpatient procedure to treat defects associated with subchondral bone marrow lesions, according to a company press release.

Zimmer Biomet reportedly received CE-mark approval to commercialize and distribute the subchondroplasty procedure in the European Union and has also received distribution approval for Canada, Singapore, Malaysia and Hong Kong.

During the procedure, bone marrow lesions are filled with the AccuFill bone substitution material. According to the release, the bone substitute is slowly resorbed and replaced with healthy bone which then repairs the bone defect.

“The international release of the subchondroplasty procedure is a major milestone for our company and for patients with chronic bone marrow lesions,” David Nolan, Zimmer Biomet group president, Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle, Office Based Technologies and Zimmer Biomet Signature Solutions, said in the release. “The procedure offers a tool that fills a gap in the patient treatment algorithm for the surgeon. We are eager to begin our international commercial launch.”

 

Reference:

www.zimmerbiomet.com

Zimmer Biomet Holdings Inc. announced the international release of the subchondroplasty procedure, a minimally invasive outpatient procedure to treat defects associated with subchondral bone marrow lesions, according to a company press release.

Zimmer Biomet reportedly received CE-mark approval to commercialize and distribute the subchondroplasty procedure in the European Union and has also received distribution approval for Canada, Singapore, Malaysia and Hong Kong.

During the procedure, bone marrow lesions are filled with the AccuFill bone substitution material. According to the release, the bone substitute is slowly resorbed and replaced with healthy bone which then repairs the bone defect.

“The international release of the subchondroplasty procedure is a major milestone for our company and for patients with chronic bone marrow lesions,” David Nolan, Zimmer Biomet group president, Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle, Office Based Technologies and Zimmer Biomet Signature Solutions, said in the release. “The procedure offers a tool that fills a gap in the patient treatment algorithm for the surgeon. We are eager to begin our international commercial launch.”

 

Reference:

www.zimmerbiomet.com